GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.

Bora and Celltrion Join Forces To Distribute Oral Drugs Across APAC

by Joy Lin
Share To

Taiwan’s Bora Pharmaceuticals and South Korea’s Celltrion Asia Pacific Pte, a subsidiary of Celltrion Group Inc, have announced a partnership to contract manufacture and bring to market a range of oral dosage form drugs (OSD) across the Asia-Pacific region. 

The oral drugs will be manufactured at Bora’s Zhunan site, which is one of the largest US FDA and MHRA-approved drug production plants in Taiwan. The manufactured products will be used to support Celltrion’s regulatory filings for approval in seven countries. 

This could include Celltrion’s oral infliximab, a tumor necrosis factor-alpha inhibitor for the treatment of inflammatory bowel disease (IBD). The company is currently advancing the formulation with UK-based Intract Pharma.  

Apart from manufacturing, Bora will also aid the commercialization of Celltrion’s products through its complex oral dosage form and total-solution services. 

“We are extremely excited about this new partnership with Celltrion. As a trusted global partner, we look forward to serving our customers with the best technology and quality resources and supporting our partners to expand into various markets around the world,” said Bobby Sheng, CEO and Chairman of Bora. 

Related article: Bora Pharmaceuticals Expands with Eden Biologics’ CDMO Purchase 

Bora Acquires TWi and Eden Biologics

As part of its five-year growth strategy, Bora has been on a buying spree for companies with manufacturing abilities. Last October, the CDMO completed the acquisition of a fellow Taiwan-based company, TWi Pharmaceutical, adding two production plants to boost formulation development, sterile ophthalmic, and niche manufacturing technologies. 

A few months earlier, Bora brought in Eden Biologics’ CDMO assets with an initial investment of $50 million and up to $100 million in a bid to rapidly scale a presence in biological macromolecules and cell and gene therapy markets. 

The latest acquisitions have brought Bora’s number of CGMP manufacturing facilities to seven across Taiwan and Canada. Besides OSD drugs, Bora also offers end-to-end services for non-sterile liquids, sterile and non-sterile ophthalmic, nasal sprays, and semi-solid pharmaceutical products. 

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
CDMO Samsung Bio Secures Record $1.24 Billion Biopharma Manufacturing Contract, Raising Total 2024 Deal Value to Over $3.3 Billion
2024-10-23
Indian CDMO Stocks in the Spotlight: US House to Vote on BIOSECURE Act Next Week
2024-09-06
Bora Pharmaceuticals Acquires 30.5% Stake in Tanvex Biopharma, Becomes Largest Corporate Shareholder
2024-08-28
LATEST
Beyond Pouch Packaging: Hanmi Pharmaceutical Introduces a New Automated Vial Dispensing Solution in Canada and the United States
2025-02-13
NASA Says There’s a 1 in 43 Chance an Asteroid 2024 YR4 Could Hit Earth in 2032—Should We Worry?
2025-02-13
Sodium Channel Targeting: What the Latest FDA Non-Opioid Approval Reveals About the Next Big Thing in Pain Relief
2025-02-12
Novartis Reclaims Abelacimab in $925M Deal to Boost Cardiovascular Portfolio
2025-02-12
GLP-1 Weight Loss Drugs Might Cause Blindness
2025-02-11
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-04
MIXiii Health-Tech.IL
Jerusalem, Israel
2025-03-05
Medical Japan
Osaka, Japan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
Scroll to Top